55P - MED12 and STAT3 influence outcome to platinum-based chemotherapy in patients (p) with advanced non-small-cell lung cancer (NSCLC)

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Daniela Morales-Espinosa
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors D. Morales-Espinosa1, N. Karachaliou2, C. Costa2, M.Á. Molina3, A. Gimenez-Capitán2, J.J. Sánchez4, B. Massuti5, L. Bonanno6, M. Majem7, R. Rosell8
  • 1Translational Research Laboratory, Institut Catalá d'Oncologia, 08916 - Badalona/ES
  • 2Translational Research, Rna Unit, Pangaea Biotech, 08028 - Barcelona/ES
  • 3Translational Research, Pangaea Biotech, 08028 - Barcelona/ES
  • 4Department Of Preventive Medicine, Facultad De Medicina,, Universidad Autónoma de Madrid, 28029 - Madrid/ES
  • 5Departamento De Oncología, Hospital General Universitario de Alicante, 03010 - Alicante/ES
  • 6Second Medical Oncology Unit, Istituto Oncologico Veneto IRCCS, 35128 - Padova/IT
  • 7Oncología Médica, Hospital de la Santa Creu i Sant Pau, 08025 - Barcelona/ES
  • 8Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916 - Badalona/ES


To examine MED12 – a negative regulator of the TGF-b receptor signaling -, IDO, IL6, RelA (NFkB), BIM and the JAK2/STAT3 pathway and KRAS in NSCLC tumor samples and correlate results with progression-free survival (PFS).